评估非感染性葡萄膜炎治疗中阿达木单抗剂量升级至每周给药的有效性:一项多中心研究
这项多中心回顾性干预性病例系列纳入50例标准每两周阿达木单抗给药控制不佳的非感染性葡萄膜炎患者,升级至每周给药6个月后52%达到治疗成功。后葡萄膜炎与治疗成功几率较高相关(OR 6.88),全葡萄膜炎与较低成功率相关(OR 0.14)。
要点
- 标准每两周阿达木单抗控制不佳的非感染性葡萄膜炎患者升级至每周给药,6个月时52%达到治疗成功。
- 后葡萄膜炎患者治疗成功OR为6.88,全葡萄膜炎患者OR为0.14。
- 升级后前房细胞分级(P=0.025)和活动性视网膜或脉络膜病灶存在(P=0.010)显著减少。
核心结论
- 从标准每两周阿达木单抗给药升级至每周给药在超过一半的患者中达到治疗成功。
- 后葡萄膜炎预示有利的成功机会,而全葡萄膜炎则成功率较低。
研究设计与样本
- 多中心回顾性干预性病例系列。
- 纳入50例接受标准每两周阿达木单抗给药的非感染性葡萄膜炎患者,来自6个三级转诊中心,升级至每周阿达木单抗给药。
- 在阿达木单抗剂量升级时和6个月后评估人口学数据和临床表现,采用混合模型分析临床结局和成功预测因素。
主要发现
- 阿达木单抗升级后6个月(中位数184天),52%的患者达到治疗成功。
- 升级后显著减少的特定炎症体征包括前房细胞分级(P=0.025)和活动性视网膜或脉络膜病灶存在(P=0.010)。
- 63%的患者泼尼松从大于7.5 mg/天降至更低剂量(P=0.015)。
- 后葡萄膜炎患者治疗成功的比值比为6.88(P=0.024),全葡萄膜炎患者为0.14(P=0.005)。
- 阿达木单抗升级时有活动性视网膜血管炎的眼部治疗成功的风险比为3.73(P=0.009)。
关键数值与推荐
- 治疗成功复合标准包括:(1)疾病静止(前房细胞≤0.5+,玻璃体混浊≤0.5+,视网膜或脉络膜病灶无活动);(2)泼尼松≤7.5 mg/天;(3)泼尼松龙或等效药物≤2滴/天;(4)未中断治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the effectiveness of adalimumab dosage escalation in patients with noninfectious uveitis that is controlled inadequately with standard dosing. DESIGN: Multicenter retrospective interventional case series. PARTICIPANTS: Patients with noninfectious uveitis receiving active standard biweekly adalimumab dosing who underwent treatment escalation to weekly adalimumab dosing at 6 tertiary referral centers. METHODS: Demographic data and clinical findings were assessed at the time of adalimumab dosage escalation and 6 months later. Mixed-model analysis was performed to analyze clinical outcomes and to assess predictive factors of success. MAIN OUTCOME MEASURES: Treatment success composite criteria included: (1) disease quiescence (≤ 0.5+ anterior chamber cell, ≤ 0.5+ vitreous haze, inactive retinal or choroidal lesions), (2) prednisone 7.5 mg/day or less, and (3) 2 drops/day or less of prednisolone or equivalent (4) no treatment discontinuation. RESULTS: Fifty patients (mean ± standard deviation age, 44.4 ± 21.2 years; n = 35 female patients) from 6 tertiary referral centers were included. At 6 months after adalimumab escalation (median, 184 days), 52% of patients had achieved treatment success. Specific inflammatory signs significantly reduced after adalimumab escalation included anterior chamber cell grade (P = 0.025) and presence of active retinal or choroidal lesions (P = 0.010). Prednisone was decreased from more than 7.5 mg/day to lower dosages in 63% of patients (P = 0.015). The odds ratio for treatment success was 6.88 for patients with posterior uveitis (P = 0.024) and 0.14 (P = 0.005) for patients with panuveitis. The hazard ratio for treatment success was 3.73 (P = 0.009) for eyes with active retinal vasculitis at the time of adalimumab escalation. CONCLUSIONS: Escalation from standard biweekly adalimumab dosing to weekly adalimumab dosing achieved treatment success in more than half of the patients. Posterior uveitis predicts a favorable chance of success, whereas panuveitis conveys a lower success rate. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
引用
- Pillar S, Thomas A, Hassman LM, et al. Evaluating the Effectiveness of Escalating to Weekly Adalimumab Dosing for the Treatment of Noninfectious Uveitis: A Multicenter Study. Ophthalmology. 2025. PMID: 41038454. doi:10.1016/j.ophtha.2025.09.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。